CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
September 10, 2024 13:09 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose...
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
September 10, 2024 07:45 ET
|
Altimmune, Inc
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related...
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
September 05, 2024 12:00 ET
|
Johnson Fistel, LLP
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is conducting a thorough investigation into possible violations of securities laws by specific officers at Sprout Social, Inc....
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
September 03, 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body...
Prader–Willi Syndrome Market is Expected to Showcase Growth at a CAGR of ~6% by 2034 | DelveInsight
August 13, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Prader–Willi Syndrome Market is Expected to Showcase Growth at a CAGR of ~6% by 2034 | DelveInsight The Prader–Willi syndrome market is...
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 08, 2024 07:00 ET
|
Altimmune, Inc
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment...
Obesity Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
August 06, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Obesity Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Obesity...
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
August 01, 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial...
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 30, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Altimmune, Inc. (NASDAQ:...
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
July 25, 2024 07:30 ET
|
Altimmune, Inc
Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment ...